Oxford BioDynamics Plc (LSE:OBD) completed a fundraise in August 2026 that it described as necessary to avoid running out of cash. The central question is why the AIM-quoted precision diagnostics company raised £9.15 million through the issue of more than nine billion shares, and what it now intends to do with the money.

A 3D genomics diagnostics business

Oxford BioDynamics, spun out of the University of Oxford in 2007, develops blood tests and research tools built on EpiSwitch, a proprietary platform that maps the three-dimensional architecture of the genome. Its commercial tests include the PSE test for prostate cancer detection and CiRT, which is designed to predict response to checkpoint inhibitor cancer immunotherapies. The company operates laboratories in Oxford, Frederick in Maryland, and Penang.

A newer strand is EpiSwitch Orion, a cloud-based platform that analyses existing genomic datasets for 3D regulatory information without new patient samples. On 28 July 2026, the company announced Orion's first commercial agreement, with the OPTIMISE programme consortium, whose members include the University of Oxford and King's College London, for work on psoriatic arthritis treatment response. Financial terms were not disclosed. Chief executive Richard Compton said: "This is the first time a partner has paid for access to Orion's capabilities."

The August placing

On 10 August 2026, the company announced a conditional placing to raise £9.15 million gross, or £8.4 million net, at 0.1 pence per share. It said the price was a 9.1% discount to the prior closing price of 0.11 pence on 7 August. The 9,150,000,000 new shares represent 68.1% of the enlarged share capital, and the joint Brokers received 260,850,000 warrants exercisable at 0.2 pence.

The company said its "existing cash resources are expected to be exhausted by early September 2026" and that "no non-dilutive transaction has yet been secured". Without the placing, it said it would have needed to seek alternative funding urgently or, failing that, a sale of the Business or an orderly wind-up.

Shareholders passed all resolutions at the general meeting on 26 August 2026, and trading in the new shares was expected to begin on AIM on 27 August, leaving 13,440,910,967 shares in issue. Directors and managers participated, including Martin Diggle, whose holding rose to 8.32%, and Mr Compton, who became a Shareholder with 2.2%.

Use of proceeds and financial position

The company said net proceeds would support Orion platform partnerships, growth of the PSE test and pursuit of US licensing, a CiRT evidence programme and NHS pilots, and pipeline development including completion of a colorectal cancer study. Together with expected operating revenues, it said the money should provide at least twelve months of working capital. The circular also disclosed a serious loss of capital under section 656 of the Companies Act 2006, meaning net Assets had fallen below half of called-up share capital.

Scientific progress and risks

On 3 September 2026, the company reported a peer-reviewed study in the Journal of Translational Medicine, led by the University of East Anglia, which used Orion to find shared regulatory networks across five fatigue-related conditions, including ME/CFS and long COVID. Such publications may support Orion's credibility but do not themselves produce revenue.

The main risks are commercial execution and funding. The company acknowledged that anticipated commercial opportunities had not yet been contracted and may not be concluded on expected terms or timescales. A twelve-month runway means further capital or Partnership income may be needed, and the heavy dilution already sustained shows the cost of Equity funding at current share prices.

Conclusion

Oxford BioDynamics raised £9.15 million because, by its own account, it was weeks from exhausting its cash and had not secured a non-dilutive deal. The placing buys roughly a year to convert Orion, PSE and CiRT progress into sustainable revenue.